绥美凯医保后的价格

What is the price of Suimeikai (Domitabalamid Tablets, Inbec) after medical insurance? Let's take a look. Suimeikai (dolute abalamide tablets, Inbec) was approved for marketing by the FDA on August 27, 2014. Subsequently, on January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation Suimeike (Dolutea Balamib Tablets, Inbec) with the new generation integrase inhibitor dolutegravir (DTG) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

According to Medical Companion Travel, Suimeikai (Domitabalamid Tablets) has just been launched in China and has not yet been included in medical insurance, and it is not yet a medical insurance drug. Since Suimeikai (Dolutea Paramid Tablets, Inbec) is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Suimeikai (Domitabalamid Tablets), which is available in India. Suimeike (Abalamid Tablets, Inbec) produced by the Indian company Emcure, comes in a box of 30 tablets, priced at approximately RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.

Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. Suimeike (Inbec) is a treatment plan with DTG, an integrase inhibitor, as the core drug, and two core drugs, abacavir and lamivudine. It is made into a single-tablet treatment and promoted, making the core drug a great improvement in HAART treatment.

In addition, Suimeikai (Domitabalamid Tablets, Inbec) can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.